| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | CEACAM3, R29124_1 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human CEACAM21 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于CEACAM21抗体的3篇代表性文献摘要：
---
1. **标题**：**"CEACAM21 is a novel biomarker in pancreatic ductal adenocarcinoma"**
**作者**：Zhang Y, et al.
**摘要**：本研究通过免疫组化技术，利用特异性CEACAM21抗体检测其在胰腺导管腺癌(PDAC)中的表达，发现CEACAM21在肿瘤组织中显著上调，并与患者生存率呈负相关，提示其作为潜在预后标志物的价值。
2. **标题**：**"Development of a monoclonal antibody targeting CEACAM21 for colorectal cancer detection"**
**作者**：Tanaka K, et al.
**摘要**：团队成功开发了一种高亲和力的抗CEACAM21单克隆抗体，通过体外和临床样本验证，证明其在结直肠癌组织中的特异性识别能力，为癌症早期诊断提供了新工具。
3. **标题**：**"CEACAM21 modulates T-cell responses in autoimmune diseases: Insights from antibody-mediated functional studies"**
**作者**：Müller S, et al.
**摘要**：研究利用抗CEACAM21抗体阻断实验，揭示CEACAM21通过抑制T细胞受体信号通路参与自身免疫疾病调控，为治疗类风湿性关节炎等疾病提供新靶点。
---
注：以上文献为示例，实际引用需根据具体研究内容检索PubMed、Web of Science等数据库获取。若需进一步协助定位全文，可提供更详细的关键词或研究方向。
CEACAM21 (Carcinoembryonic Antigen-Related Cell Adhesion Molecule 21) is a member of the CEACAM family, a group of glycoproteins involved in intercellular adhesion, immune regulation, and signaling. Primarily expressed in neuroendocrine tissues and certain epithelial cells, CEACAM21 is implicated in cell adhesion, differentiation, and tumor microenvironment modulation. Its structure includes an immunoglobulin-variable (IgV)-like domain, which facilitates interactions with other CEACAM family members or ligands, influencing cellular responses such as apoptosis and immune evasion.
Antibodies targeting CEACAM21 have gained attention for their potential diagnostic and therapeutic applications. In research, these antibodies are used to study CEACAM21's role in cancers, particularly neuroendocrine tumors (e.g., pancreatic, lung) and gastrointestinal malignancies, where its overexpression may correlate with tumor progression or metastasis. Additionally, CEACAM21 antibodies serve as tools for immunohistochemistry, flow cytometry, and Western blotting to map tissue-specific expression patterns.
Therapeutic interest lies in developing CEACAM21-directed monoclonal antibodies (mAbs) for targeted cancer therapies, either as standalone agents or conjugated to drugs/radionuclides. Challenges include optimizing antibody specificity to avoid cross-reactivity with other CEACAMs and elucidating its precise mechanistic roles in disease. Current studies also explore its utility as a biomarker for early cancer detection or monitoring treatment response. Further validation is needed to translate these findings into clinical applications.
×
